tradingkey.logo

爱尔康

ALC
79.190USD
+0.390+0.49%
收盘 12/15, 16:00美东报价延迟15分钟
39.17B总市值
37.40市盈率 TTM

爱尔康

79.190
+0.390+0.49%

关于 爱尔康 公司

Alcon AG is a Switzerland-based eye care company. The Company research, develop, manufacture, distribute and sell a full suite of eye care products within two key businesses: Surgical and Vision Care. The Company’s Surgical business is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery. The surgical portfolio includes implantables, consumables and surgical equipment required for these procedures and supports the end-to-end needs of the ophthalmic surgeon. The Company’s Vision Care business comprises of daily disposable, reusable and color-enhancing contact lenses and a portfolio of ocular health products, including products for dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The Company operates in 60 countries and serves consumers and patients in over 140 countries.

爱尔康简介

公司代码ALC
公司名称Alcon AG
上市日期Apr 09, 2019
CEOEndicott (David J)
员工数量25599
证券类型Ordinary Share
年结日Apr 09
公司地址Rue Louis d'Affry 6
城市FRIBOURG
上市交易所NASDAQ OMX NASDAQ Basic NYSE
国家Switzerland
邮编1700
电话41589113800
网址https://www.alcon.ch/
公司代码ALC
上市日期Apr 09, 2019
CEOEndicott (David J)

爱尔康公司高管

名称
名称/职务
职务
持股
持股变动
Mr. David J. Endicott
Mr. David J. Endicott
Chief Executive Officer, Director
Chief Executive Officer, Director
207.11K
-11.08%
Mr. Timothy C. (Tim) Stonesifer
Mr. Timothy C. (Tim) Stonesifer
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
134.23K
+38.34%
Mr. Rajkumar Narayanan
Mr. Rajkumar Narayanan
Senior Vice President, President - International
Senior Vice President, President - International
37.83K
+9.30%
Mr. Ian Bell
Mr. Ian Bell
Chief Operating Officer, Senior Vice President
Chief Operating Officer, Senior Vice President
30.23K
-24.88%
Ms. Karen J. May, CPA
Ms. Karen J. May, CPA
Independent Director
Independent Director
28.32K
+11.14%
Mr. Laurent Attias
Mr. Laurent Attias
Senior Vice President - Corporate Strategy, Business Development and Licensing (BD&L) and Mergers and Acquisitions (M&A)
Senior Vice President - Corporate Strategy, Business Development and Licensing (BD&L) and Mergers and Acquisitions (M&A)
22.62K
+15.19%
Mr. Scott Harlan Maw
Mr. Scott Harlan Maw
Independent Director
Independent Director
17.26K
+14.57%
Ms. Ines Poeschel
Ms. Ines Poeschel
Independent Director
Independent Director
12.08K
+15.09%
Ms. Lynn Dorsey Bleil
Ms. Lynn Dorsey Bleil
Independent Director
Independent Director
10.94K
+13.26%
Ms. Deborah Di Sanzo
Ms. Deborah Di Sanzo
Director
Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. David J. Endicott
Mr. David J. Endicott
Chief Executive Officer, Director
Chief Executive Officer, Director
207.11K
-11.08%
Mr. Timothy C. (Tim) Stonesifer
Mr. Timothy C. (Tim) Stonesifer
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
134.23K
+38.34%
Mr. Rajkumar Narayanan
Mr. Rajkumar Narayanan
Senior Vice President, President - International
Senior Vice President, President - International
37.83K
+9.30%
Mr. Ian Bell
Mr. Ian Bell
Chief Operating Officer, Senior Vice President
Chief Operating Officer, Senior Vice President
30.23K
-24.88%
Ms. Karen J. May, CPA
Ms. Karen J. May, CPA
Independent Director
Independent Director
28.32K
+11.14%
Mr. Laurent Attias
Mr. Laurent Attias
Senior Vice President - Corporate Strategy, Business Development and Licensing (BD&L) and Mergers and Acquisitions (M&A)
Senior Vice President - Corporate Strategy, Business Development and Licensing (BD&L) and Mergers and Acquisitions (M&A)
22.62K
+15.19%

收入明细

单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
业务USD
名称
营收
占比
Consumables
777.00M
30.15%
Contact lenses
692.00M
26.85%
Implantables
456.00M
17.69%
Ocular health
430.00M
16.69%
Equipment/other
222.00M
8.61%
Sales to Novartis Group
19.00M
0.74%
地区USD
名称
营收
占比
International
1.42B
54.99%
United States
1.16B
45.01%
业务
地区
业务USD
名称
营收
占比
Consumables
777.00M
30.15%
Contact lenses
692.00M
26.85%
Implantables
456.00M
17.69%
Ocular health
430.00M
16.69%
Equipment/other
222.00M
8.61%
Sales to Novartis Group
19.00M
0.74%

股东统计

更新时间: 11月27日 周四
更新时间: 11月27日 周四
持股股东
股东类型
持股股东
持股股东
占比
BlackRock Advisors (UK) Limited
4.94%
The Vanguard Group, Inc.
4.20%
UBS Fund Management (Switzerland) AG
2.29%
Norges Bank Investment Management (NBIM)
2.27%
Aristotle Capital Management, LLC
2.14%
其他
84.16%
持股股东
持股股东
占比
BlackRock Advisors (UK) Limited
4.94%
The Vanguard Group, Inc.
4.20%
UBS Fund Management (Switzerland) AG
2.29%
Norges Bank Investment Management (NBIM)
2.27%
Aristotle Capital Management, LLC
2.14%
其他
84.16%
股东类型
持股股东
占比
Investment Advisor
31.53%
Investment Advisor/Hedge Fund
24.78%
Bank and Trust
4.10%
Sovereign Wealth Fund
2.35%
Hedge Fund
2.09%
Research Firm
1.93%
Pension Fund
1.41%
Individual Investor
0.13%
Insurance Company
0.07%
其他
31.62%

机构持股

更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
1623
342.44M
72.26%
+507.76K
2025Q3
1664
342.40M
72.42%
-9.24M
2025Q2
1658
350.50M
70.82%
+3.47M
2025Q1
1649
340.47M
77.49%
-46.78M
2024Q4
1637
370.92M
68.31%
+36.10M
2024Q3
1614
334.31M
67.55%
+3.20M
2024Q2
1581
336.83M
74.41%
-28.77M
2024Q1
1567
336.16M
66.45%
+4.09M
2023Q4
1583
325.43M
67.42%
+1.37M
2023Q3
1565
323.23M
69.34%
-9.13M
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
BlackRock Advisors (UK) Limited
24.68M
4.94%
--
--
Dec 31, 2024
The Vanguard Group, Inc.
20.64M
4.13%
+781.14K
+3.93%
Jun 30, 2025
UBS Fund Management (Switzerland) AG
11.47M
2.29%
-68.71K
-0.60%
Jun 30, 2025
Norges Bank Investment Management (NBIM)
11.35M
2.27%
-1.28M
-10.12%
Jun 30, 2025
Aristotle Capital Management, LLC
12.04M
2.41%
-191.15K
-1.56%
Jun 30, 2025
T. Rowe Price Associates, Inc.
6.98M
1.4%
+2.06M
+41.82%
Jun 30, 2025
Zürcher Kantonalbank (Asset Management)
9.14M
1.83%
+628.34K
+7.38%
Jun 30, 2025
AKO Capital LLP
7.71M
1.54%
+597.84K
+8.40%
Jun 30, 2025
Fidelity Management & Research Company LLC
10.21M
2.04%
-4.82M
-32.06%
Jun 30, 2025
Select Equity Group, L.P.
6.76M
1.35%
+1.28M
+23.44%
Jun 30, 2025
查看更多

持股ETF

更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
Global X Aging Population ETF
2.36%
Franklin FTSE Switzerland ETF
2.28%
iShares MSCI Switzerland ETF
2.2%
First Trust Indxx Medical Devices ETF
2.06%
Running Oak Efficient Growth ETF
1.77%
Global X S&P Catholic Values Developed ex-US ETF
1.07%
JPMorgan BetaBuilders Europe ETF
0.59%
iShares Global Healthcare ETF
0.53%
ALPS O'Shares International Developed Quality Dividend ETF
0.45%
Wahed Dow Jones Islamic World ETF
0.44%
查看更多
Global X Aging Population ETF
占比2.36%
Franklin FTSE Switzerland ETF
占比2.28%
iShares MSCI Switzerland ETF
占比2.2%
First Trust Indxx Medical Devices ETF
占比2.06%
Running Oak Efficient Growth ETF
占比1.77%
Global X S&P Catholic Values Developed ex-US ETF
占比1.07%
JPMorgan BetaBuilders Europe ETF
占比0.59%
iShares Global Healthcare ETF
占比0.53%
ALPS O'Shares International Developed Quality Dividend ETF
占比0.45%
Wahed Dow Jones Islamic World ETF
占比0.44%

分红派息

近5年累计派现 400.00M 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
Mar 01, 2022
ALC.NB Final Cash Dividend of gross CHF 0.2 paid on May 05, 2022 going ex on Apr 29, 2022
May 04, 2022
May 05, 2022
May 03, 2022
Feb 24, 2021
ALC.NB Final Cash Dividend of gross CHF 0.1 paid on May 06, 2021 going ex on May 04, 2021
May 05, 2021
May 06, 2021
May 04, 2021

拆合股

公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据

常见问题

爱尔康的前五大股东是谁?

爱尔康 的前五大股东如下:
BlackRock Advisors (UK) Limited持有股份:24.68M,占总股份比例:4.94%。
The Vanguard Group, Inc.持有股份:20.64M,占总股份比例:4.13%。
UBS Fund Management (Switzerland) AG持有股份:11.47M,占总股份比例:2.29%。
Norges Bank Investment Management (NBIM)持有股份:11.35M,占总股份比例:2.27%。
Aristotle Capital Management, LLC持有股份:12.04M,占总股份比例:2.41%。

爱尔康的前三大股东类型是什么?

爱尔康 的前三大股东类型分别是:
BlackRock Advisors (UK) Limited
The Vanguard Group, Inc.
UBS Fund Management (Switzerland) AG

有多少机构持有爱尔康(ALC)的股份?

截至2025Q4,共有1623家机构持有爱尔康的股份,合计持有的股份价值约为342.44M,占公司总股份的72.26%。与2025Q3相比,机构持股有所增加,增幅为-0.16%。

哪个业务部门对爱尔康的收入贡献最大?

在FY2025Q2,Consumables业务部门对爱尔康的收入贡献最大,创收777.00M,占总收入的30.15%。
KeyAI